This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-10. Anything still debated is marked as such rather than presented as settled.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
== History == Oxandrolone was first made by Raphael Pappo and Christopher J. Jung while at Searle Laboratories, now part of Pfizer and they first described the drug in 1962. They were immediately interested in oxandrolone's very weak androgenic effects relative to its anabolic effects. It was introduced as a pharmaceutical drug in the United States in 1964. Oxandrolone was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss, and is used as part of treatment for HIV/AIDS. It had also been shown to be partially successful in treating cases of osteoporosis. However, in 1989, in part due to bad publicity from its illicit use by bodybuilders, production of Anavar was discontinued by Searle Laboratories. It was picked up by Bio-Technology General Corporation, which changed its name to Savient Pharmaceuticals. In 1995, following successful clinical trials, Savient released it under the brand name Oxandrin. As of 2011 BTG subsequently had won approvals for orphan drug status by the Food and Drug Administration for treating alcoholic hepatitis, Turner syndrome, and HIV-induced weight loss and as an offset to protein catabolism caused by long-term administration of corticosteroids.
However, a 2021 study on the decay chains of flerovium isotopes suggests that there is no strong stabilizing effect from Z = 114 in the region of known nuclei (N = 174), and that extra stability would be predominantly a consequence of the neutron shell closure. Although known nuclei still fall several neutrons short of N = 184 where maximum stability is expected (the most neutron-rich confirmed nuclei, 293Lv and 294Ts, only reach N = 177), and the exact location of the center of the island remains unknown, the trend of increasing stability closer to N = 184 has been demonstrated. For example, the isotope 285Cn, with eight more neutrons than 277Cn, has a half-life almost five orders of magnitude longer. This trend is expected to continue into unknown heavier isotopes in the vicinity of the shell closure.
This multidisciplinary approach allows researchers to identify vulnerable populations, characterize disparities in dementia incidence and outcomes, and evaluate interventions that may delay cognitive decline and improve quality of life for aging individuals. A defining strength of CAPAS is its emphasis on health equity and the study of historically underrepresented populations. Investigators examine racial, ethnic, geographic, and socioeconomic disparities in dementia risk, diagnosis, treatment, caregiving, and healthcare utilization, with particular attention to Hispanic, rural, and medically underserved communities throughout South Texas and the United States. By investigating the social determinants of brain health alongside biological mechanisms of aging, the Center provides critical insights into why dementia disproportionately affects certain populations and identifies opportunities to reduce inequities through targeted prevention strategies, public health initiatives, and healthcare policy. The Center also serves as an important resource for methodological innovation in population aging research. Faculty develop and apply advanced analytical approaches—including longitudinal data analysis, causal inference methods, machine learning, geospatial analysis, and health services research—to better understand the complex interactions among aging, chronic disease, cognitive decline, and social determinants of health.
Sources: en.wikipedia.org
Brown fat or brown adipose tissue (BAT) is a specialized form of adipose tissue important for adaptive thermogenesis in humans and other mammals. BAT can generate heat by "uncoupling" the respiratory chain of oxidative phosphorylation within mitochondria through tissue-specific expression of uncoupling protein 1 (UCP1). BAT is primarily located around the neck and large blood vessels of the thorax, where it may effectively act in heat exchange. BAT is robustly activated upon cold exposure by the release of catecholamines from sympathetic nerves that results in UCP1 activation. Nearly half of the nerves present in adipose tissue are sensory neurons connected to the dorsal root ganglia. BAT activation may also occur in response to overfeeding. UCP1 activity is stimulated by long chain fatty acids that are produced subsequent to β-adrenergic receptor activation. UCP1 is proposed to function as a fatty acid proton symporter, although the exact mechanism has yet to be elucidated. In contrast, UCP1 is inhibited by ATP, ADP, and GTP. Attempts to simulate this process pharmacologically have so far been unsuccessful. Techniques to manipulate the differentiation of "brown fat" could become a mechanism for weight loss therapy in the future, encouraging the growth of tissue with this specialized metabolism without inducing it in other organs. A review on the eventual therapeutic targeting of brown fat to treat human obesity was published by Samuelson and Vidal-Puig in 2020.
Glycolysis and glycogenolysis defects: McArdle's disease, phosphofructokinase deficiency, glycogen storage diseases VIII, IX, X and XI Lipid metabolism defects: carnitine palmitoyltransferase I and II deficiency, deficiency of subtypes of acyl CoA dehydrogenase (LCAD, SCAD, MCAD, VLCAD, 3-hydroxyacyl-coenzyme A dehydrogenase deficiency), thiolase deficiency Mitochondrial myopathies: deficiency of succinate dehydrogenase, cytochrome c oxidase and coenzyme Q10 Others: glucose-6-phosphate dehydrogenase deficiency, myoadenylate deaminase deficiency and muscular dystrophies
We feel that the Arabs and Jews are cousins in race, suffering similar oppression at the hands of powers stronger than themselves, and by a happy coincidence have been able to take the first step toward the attainment of their national ideals together. We Arabs, especially the educated among us, look with deepest sympathy on the Zionist movement ... We will do our best, in so far as we are concerned, to help them through; we will wish the Jews a most hearty welcome home.When the letter was tabled at the Shaw Commission in 1929, Rustam Haidar spoke to Faisal in Baghdad and cabled that Faisal had "no recollection that he wrote anything of the sort". In January 1930, Haidar wrote to a newspaper in Baghdad that Faisal: "finds it exceedingly strange that such a matter is attributed to him as he at no time would consider allowing any foreign nation to share in an Arab country". Awni Abd al-Hadi, Faisal's secretary, wrote in his memoirs that he was not aware that a meeting between Frankfurter and Faisal took place and that: "I believe that this letter, assuming that it is authentic, was written by Lawrence, and that Lawrence signed it in English on behalf of Faisal. I believe this letter is part of the false claims made by Chaim Weizmann and Lawrence to lead astray public opinion." According to Allawi, the most likely explanation for the Frankfurter letter is that a meeting took place, a letter was drafted in English by Lawrence, but that its "contents were not entirely made clear to Faisal.
== Other metalloenzymes == There are two types of carbon monoxide dehydrogenase: one contains iron and molybdenum, the other contains iron and nickel. Parallels and differences in catalytic strategies have been reviewed. Pb2+ (lead) can replace Ca2+ (calcium) as, for example, with calmodulin or Zn2+ (zinc) as with metallocarboxypeptidases. A new class of Heme oxygenase (HO)-like metalloenzymes class has been identified. Some other metalloenzymes are given in the following table, according to the metal involved.
Sources: en.wikipedia.org
Israel has installed a variant of the Samson RCWS, a remote controlled weapons platform, which can include machine guns, grenade launchers, and anti-tank missiles on a remotely operated turret, in pillboxes along the Israeli Gaza Strip barrier to prevent Palestinian militants from entering its territory. Israel has developed observation balloons equipped with sophisticated cameras and surveillance systems used to thwart terror attacks from Gaza. The Ground Forces possess advanced combat engineering equipment including the IDF Caterpillar D9 armored bulldozer, IDF Puma combat engineering vehicle, Tzefa Shiryon and CARPET minefield breaching rockets, and a variety of robots and explosive devices.
The flowers may be arranged along the stem, developing from the base, as a single flower at the tip of the stem, or as a cluster of flowers. They contain both male (androecium) and female (gynoecium) characteristics and are symmetric radially, but sometimes as a mirror image. Most flowers are large and colourful, except for Medeoleae. Both the petals and sepals are usually similar and appear as two concentric groups (whorls) of 'petals', that are often striped or multicoloured, and produce nectar at their bases. The stamens are usually in two groups of three (trimerous) and the pollen has a single groove (monosulcate). The ovary is located above the attachment of the other parts (superior). There are three fused carpels (syncarpus) with one to three chambers (locules), a single style and a three-lobed stigma. The embryo sac is of the Fritillaria type. Usually indeterminate (lacking terminal flower) as a raceme (Lilium); sometimes reduced to a single terminal flower (Tulipa). When pluriflor (multiple blooms), the flowers are arranged in a cluster or rarely are subumbellate (Gagea) or a thyrse (spike). The flowers are hermaphroditic, actinomorphic (radially symmetric) or slightly zygomorphic (bilaterally symmetric), pedicellate (on a short secondary stem), generally large and showy but may be inconspicuous (Medeoleae). The bracts may (bracteate) or may not (ebracteate) be present.
frameshift mutation A type of mutation in a nucleic acid sequence caused by the insertion or deletion of a number of nucleotides that is not divisible by three. Because of the triplet nature by which nucleotides code for amino acids, a mutation of this sort causes a shift in the reading frame of the nucleotide sequence, resulting in the sequence of codons downstream of the mutation site being completely different from the original.
=== Arrival in Washington === Nixon had been elected in 1968 on the promise of achieving "peace with honor" and ending the Vietnam War. By promising to continue the peace talks which Johnson began in May 1968 in Paris, Nixon admitted that he had ruled out "a military victory" in Vietnam. Nixon wanted a diplomatic settlement similar to the armistice of Panmunjom that ended the Korean War and frequently stated in private he had no intention of being "the first president of the United States to lose a war". To force the North Vietnamese to sign an armistice, Nixon favored a two-pronged approach of the "madman theory" of seeking to act rashly to intimidate the North Vietnamese while at the same time trying using the strategy of "linkage" to improve relations with the Soviet Union and China in order to persuade both these nations to stop sending arms to North Vietnam. In office, Nixon implemented a policy of Vietnamization that aimed to gradually withdraw U.S. troops while expanding the combat role of the South Vietnamese Army so that it would be capable of independently defending its government against the National Front for the Liberation of South Vietnam, a Communist guerrilla organization, and the North Vietnamese army (Vietnam People's Army or PAVN). Kissinger was opposed to Vietnamization.
==== Other parameters ==== Advanced hematology analyzers generate novel measurements of blood cells which have shown diagnostic significance in research studies but have not yet found widespread clinical use. For example, some types of analyzers produce coordinate readings indicating the size and position of each white blood cell cluster. These parameters (termed cell population data) have been studied as potential markers for blood disorders, bacterial infections and malaria. Analyzers that use myeloperoxidase staining to produce differential counts can measure white blood cells' expression of the enzyme, which is altered in various disorders. Some instruments can report the percentage of red blood cells that are hypochromic in addition to reporting the average MCHC value, or provide a count of fragmented red cells (schistocytes), which occur in some types of hemolytic anemia. Because these parameters are often specific to particular brands of analyzers, it is difficult for laboratories to interpret and compare results.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.